MoonLake Immunotherapeutics
MLTX
$17.80
-$0.20-1.11%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 46.46M | 41.97M | 41.98M | 38.56M | 34.54M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 267.37M | 244.84M | 229.20M | 200.88M | 170.76M |
| Operating Income | -267.37M | -244.84M | -229.20M | -200.88M | -170.76M |
| Income Before Tax | -258.39M | -229.71M | -213.30M | -178.74M | -147.46M |
| Income Tax Expenses | 1.08M | 611.00K | 404.00K | 381.00K | 365.00K |
| Earnings from Continuing Operations | -259.47 | -230.32 | -213.70 | -179.12 | -147.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.39M | 3.00M | 3.20M | 2.96M | 2.62M |
| Net Income | -257.08M | -227.32M | -210.50M | -176.16M | -145.21M |
| EBIT | -267.37M | -244.84M | -229.20M | -200.88M | -170.76M |
| EBITDA | -264.29M | -242.22M | -226.97M | -199.04M | -169.32M |
| EPS Basic | -3.87 | -3.52 | -3.33 | -2.79 | -2.30 |
| Normalized Basic EPS | -2.39 | -2.18 | -2.06 | -1.72 | -1.42 |
| EPS Diluted | -3.87 | -3.52 | -3.33 | -2.79 | -2.30 |
| Normalized Diluted EPS | -2.39 | -2.18 | -2.06 | -1.72 | -1.42 |
| Average Basic Shares Outstanding | 265.89M | 257.85M | 252.96M | 252.48M | 252.08M |
| Average Diluted Shares Outstanding | 265.89M | 257.85M | 252.96M | 252.48M | 252.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |